Is this an immunotherapy or chemotherapy drug?

Official answer

by Drugs.com

Lenvatinib (brand name: Lenvima) is considered a targeted treatment, not a chemotherapy drug. A targeted cancer treatment works by affecting specific target molecules that lead to the growth and spread of cancer. Lenvatinib blocks cell proteins and signals directed at blood vessels that help the cancer to survive. These types of drugs are often referred to as “precision medicine”.

What is a targeted cancer treatment?

Targeted therapies are specifically designed to interact with their target, not generally with all cells (although they may affect other cells and cause side effects).

Targeted drugs block tumor cell growth (cytostatic), whereas standard chemotherapy agents typically kill tumor cells directly (are cytotoxic).

Targeted drug therapies can be used alone or with other cancer treatments. For example, lenvatinib is used in combination with pembrolizumab (Keytruda), an immunotherapy, for the treatment of endometrial cancer.

Chemotherapy (“chemo”) acts directly to kill rapidly dividing cancerous, but can also affect rapidly dividing normal cells (like hair follicles) and lead to other side effects.

Chemotherapy can be used with other treatments, such as surgery, radiation or immunotherapy, for an overall treatment regimen.

Chemotherapy can lead to serious side effects because it also can affect cells that are not cancerous.

Examples of traditional chemotherapy drugs include doxorubicin (Adriamycin) or paclitaxel.

Immunotherapy drugs do not attack cancer cells directly. Immunotherapy helps to boost your natural immune system to fight off diseases such as cancer.

These drugs stimulate the patient’s own immune system to recognize cancer cells as foreign bodies and attack these cancer cells.

However, immunotherapy can also target normal cells in your body which may lead to side effects.

Immunotherapy can be given alone or in combination with other types of cancer treatments.

Examples of common immunotherapy drugs include pembrolizumab (Keytruda) and nivolumab (Opdivo).

What is the mechanism of action of lenvatinib?

Lenvatinib is classified as an oral multiple receptor tyrosine kinase (RTK) inhibitor that blocks certain proteins that boost cancer cell growth.

It is also called a Vascular endothelial growth factor (VEGF)/ vascular endothelial growth factor receptor (VEGFR) inhibitor. It blocks signals to help slow down the growth of new blood vessels from existing blood vessels (angiogenesis) that support the tumor's growth.

Abnormal angiogenesis can occur in cancer, degenerative eye diseases and other medical conditions that involve inflammation.

The FDA first approved Eisai’s Lenvima in February 2015. It is approved for the treatment of differentiated thyroid cancer, advanced renal cell carcinoma (kidney cancer), inoperable hepatocellular (liver) carcinoma (HCC), and endometrial cancer.

Bottom Line

Lenvatinib (brand name: Lenvima) is considered an oral targeted treatment, not a chemotherapy drug.

It blocks proteins on cells and signals directed at blood vessels to help slow down the growth and spread of certain types of cancer.

It is approved for the treatment of certain forms of thyroid cancer, kidney cancer, liver cancer and endometrial cancer.

This is not all the information you need to know about lenvatinib for safe and effective use. Review the full lenvatinib information here, and discuss this information and any questions with your doctor or other health care provider.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.